New York, NY 9/14/18—BelHealth Investment Partners has purchased Gemini Bio-Products for an undisclosed amount. Based in California, Gemini Bio-Products provides biological reagents, including cell culture media and sera. “We developed a thesis to invest in supplying the burgeoning field of cell therapy and regenerative medicines. Gemini is the perfect investment for our thesis,” said Harold S. Blue, managing partner of BelHealth. “As the biotechnology field continues to evolve, these companies will require more quality biological reagents to create world-class therapies, and will look to rely on high-quality, experienced vendors like Gemini. The company has proven its high-touch service and ability to make customized solutions, which positions it very well for robust growth.” BelHealth plans to supplement the investment with acquisitions of other biological reagent firms.

Established in 1985, Gemini Bio-Products currently has a sales staff of 15, according to its website. BelHealth’s first investment in a lab reagent company, according to the portfolio companies listed on its website.